RGD Reference Report - Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial.

General

Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial.
Authors:	Broyl, A Corthals, SL Jongen, JL Van der Holt, B Kuiper, R De Knegt, Y Van Duin, M El Jarari, L Bertsch, U Lokhorst, HM Durie, BG Goldschmidt, H Sonneveld, P
Citation:	Broyl A, etal., Lancet Oncol. 2010 Nov;11(11):1057-65. Epub 2010 Sep 21.
RGD ID:	5686413
Pubmed:	PMID:20864405 (View Abstract at PubMed)
DOI:	DOI:10.1016/S1470-2045(10)70206-0 (Journal Full-text)
BACKGROUND: Bortezomib-induced peripheral neuropathy is a dose-limiting toxicity in patients with multiple myeloma, often requiring adjustment of treatment and affecting quality of life. We investigated the molecular profiles of early-onset (within one treatment cycle) versus late-onset (after two or three treatment cycles) bortezomib-induced peripheral neuropathy and compared them with those of vincristine-induced peripheral neuropathy during the induction phase of a prospective phase 3 trial. METHODS: In the induction phase of the HOVON-65/GMMG-HD4 trial, patients (aged 18-65 years) with newly diagnosed Salmon and Durie stage 2 or 3 multiple myeloma were randomly assigned to three cycles of bortezomib-based or vincristine-based induction treatment. We analysed the gene expression profiles and single-nucleotide polymorphisms (SNPs) of pretreatment samples of myeloma plasma cells and peripheral blood, respectively. This study is registered, number ISRCTN64455289. FINDINGS: We analysed gene expression profiles of myeloma plasma cells from 329 (39%) of 833 patients at diagnosis, and SNPs in DNA samples from 369 (44%) patients. Early-onset bortezomib-induced peripheral neuropathy was noted in 20 (8%) patients, and 63 (25%) developed the late-onset type. Early-onset and late-onset vincristine-induced peripheral neuropathy was noted in 11 (4%) and 17 (7%) patients, respectively. Significant genes in myeloma plasma cells from patients that were associated with early-onset bortezomib-induced peripheral neuropathy were the enzyme coding genes RHOBTB2 (upregulated by 1.59 times; p=4.5x10(-5)), involved in drug-induced apoptosis, CPT1C (1.44 times; p=2.9x10(-7)), involved in mitochondrial dysfunction, and SOX8 (1.68 times; p=4.28x10(-13)), involved in development of peripheral nervous system. Significant SNPs in the same patients included those located in the apoptosis gene caspase 9 (odds ratio [OR] 3.59, 95% CI 1.59-8.14; p=2.9x10(-3)), ALOX12 (3.50, 1.47-8.32; p=3.8x10(-3)), and IGF1R (0.22, 0.07-0.77; p=8.3x10(-3)). In late-onset bortezomib-induced peripheral neuropathy, the significant genes were SOD2 (upregulated by 1.18 times; p=9.6x10(-3)) and MYO5A (1.93 times; p=3.2x10(-2)), involved in development and function of the nervous system. Significant SNPs were noted in inflammatory genes MBL2 (OR 0.49, 95% CI 0.26-0.94; p=3.0x10(-2)) and PPARD (0.35, 0.15-0.83; p=9.1x10(-3)), and DNA repair genes ERCC4 (2.74, 1.56-4.84; p=1.0x10(-3)) and ERCC3 (1.26, 0.75-2.12; p=3.3x10(-3)). By contrast, early-onset vincristine-induced peripheral neuropathy was characterised by upregulation of genes involved in cell cycle and proliferation, including AURKA (3.31 times; p=1.04x10(-2)) and MKI67 (3.66 times; p=1.82x10(-3)), and the presence of SNPs in genes involved in these processes-eg, GLI1 (rs2228224 [0.13, 0.02-0.97, p=1.18x10(-2)] and rs2242578 [0.14, 0.02-1.12, p=3.00x10(-2)]). Late-onset vincristine-induced peripheral neuropathy was associated with the presence of SNPs in genes involved in absorption, distribution, metabolism, and excretion-eg, rs1413239 in DPYD (3.29, 1.47-7.37, 5.40x10(-3)) and rs3887412 in ABCC1 (3.36, 1.47-7.67, p=5.70x10(-3)). INTERPRETATION: Our results strongly suggest an interaction between myeloma-related factors and the patient's genetic background in the development of treatment-induced peripheral neuropathy, with different molecular pathways being implicated in bortezomib-induced and vincristine-induced peripheral neuropathy.

RGD Manual Disease Annotations Click to see Annotation Detail View

Only show annotations with direct experimental evidence (0 objects hidden)

Term	Qualifier	Evidence	With	Reference	Notes	Source	Original Reference(s)
toxic encephalopathy		IAGP		5686413	DNA: snp: intron: rs1879612: bortezomib induced	RGD
toxic encephalopathy		ISO	IGF1R (Homo sapiens)	5686413; 5686413	DNA: snp: intron: rs1879612: bortezomib induced	RGD

Objects Annotated

Genes (Rattus norvegicus)

Igf1r (insulin-like growth factor 1 receptor)

Genes (Mus musculus)

Igf1r (insulin-like growth factor I receptor)

Genes (Homo sapiens)

IGF1R (insulin like growth factor 1 receptor)

Objects referenced in this article

Gene	MKI67	marker of proliferation Ki-67	Homo sapiens
Gene	Mki67	antigen identified by monoclonal antibody Ki 67	Mus musculus
Gene	Mki67	marker of proliferation Ki-67	Rattus norvegicus

Additional Information

Gene Annotator (Functional Annotation) unavailable	Gene Annotator (Annotation Distribution) unavailable	Variant Visualizer (Genomic Variants) unavailble Variant Visualizer (Genomic Variants) unavailable
Gene Annotator (Functional Annotation)	Gene Annotator (Annotation Distribution)	Variant Visualizer (Genomic Variants)

InterViewer (Protein-Protein Interactions) unavailable	Gviewer (Genome Viewer) unavailable	Variant Visualizer (Damaging Variants) unavailble Variant Visualizer (Damaging Variants) unavailable
InterViewer (Protein-Protein Interactions)	GViewer (Genome Viewer)	Variant Visualizer (Damaging Variants)

Gene Annotator (Annotation Comparison) unavailable	OLGA (Gene List Generator) unavailable
Gene Annotator (Annotation Comparison)	OLGA (Gene List Generator)	Excel (Download)

MOET (Multi-Ontology Enrichement) unavailable	GOLF (Gene-Ortholog Location Finder) unavailable
MOET (Multi-Ontology Enrichement)	GOLF (Gene-Ortholog Location Finder)

Create Name:

Description:

Send us a Message

Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial.